Recap: Akebia Therapeutics Q4 Earnings
Portfolio Pulse from Benzinga Insights
Akebia Therapeutics (NASDAQ:AKBA) reported Q4 earnings, beating estimates with an EPS of $0.0 against an expected -$0.04 and revenue increase of $1.02 million year-over-year. This follows a previous quarter where missing EPS estimates led to a 5% share price drop.
March 14, 2024 | 9:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Akebia Therapeutics reported a significant beat on Q4 earnings with an EPS of $0.0 against an expected -$0.04, and a year-over-year revenue increase of $1.02 million.
Beating earnings estimates typically leads to positive investor sentiment and can result in a stock price increase, especially considering the company's recovery from a previous earnings miss that led to a 5% share price drop.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100